ArticleGlobal health action2023
Impact of randomised
Article in Global health action, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Strategies forOne health (Amsterdam, Netherlands) · 2026Review
- Navigating evidence-informed decision making for arboviral disease control in Pacific Island countries.BMC global and public health · 2026Review
- The L1014F Kdr mutation is associated with a higher prevalence and load of the Plasmodium-blocking symbiont Microsporidia MB In Anopheles Gambiae s.l. In Benin.BMC microbiology · 2026Article
- Managing and controlling diseases transmitted by Aedes mosquitoes: a review on best practices.Tropical medicine and health · 2026Review
- Prevention and control of dengue and Aedes mosquitoes in South and Southeast Asia: Interventions, challenges, and future recommendations.Dialogues in health · 2025Review
- Must Epidemiologically Impactful Vector Control Interventions Disrupt Mosquito Population Structure? A Case Study of a Cluster-Randomised Controlled Trial.Evolutionary applications · 2025Article
- Long-Term Durability and Public Health Impact of City-WideTropical medicine and infectious disease · 2025Article
- Proceedings of the 7Vaccines · 2025Article
- Resistance status ofNarra J · 2025Review
- ExploitingPathogens (Basel, Switzerland) · 2025Review
- Article
- Review
- Review
- Dengue virus genomic surveillance in the applying Wolbachia to eliminate dengue trial reveals genotypic efficacy and disruption of focal transmission.Scientific reports · 2024Article
- The Plasmodium transmission-blocking symbiont, Microsporidia MB, is vertically transmitted through Anopheles arabiensis germline stem cells.PLoS pathogens · 2024Article
- RevisitingEcology and evolution · 2024Article
- Reanalysis of cluster randomised trial data to account for exposure misclassification using a per-protocol and complier-restricted approach.Scientific reports · 2024Article
- Updates on traditional methods for combating malaria and emergingFrontiers in cellular and infection microbiology · 2024Review
- A comprehensive review ofFrontiers in immunology · 2024Review
- Utility of surveillance data for planning for dengue elimination in Yogyakarta, Indonesia: a scenario-tree modelling approach.BMJ global health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundReleases of Wolbachia (
objectiveIn this predefined analysis, we evaluated the impact of the wMel deployments in Yogyakarta on dengue hemorrhagic fever (DHF) case notifications and on the frequency of perifocal insecticide spraying by public health teams.
methodsMonthly counts of DHF cases notified to the Yogyakarta District Health Office between January 2006 and May 2022 were modelled as a function of time-varying local wMel treatment status (fully- and partially-treated vs untreated, and by quintile of wMel prevalence). The frequency of insecticide fogging in wMel-treated and untreated areas was analysed using negative binomial regression.
resultsNotified DHF incidence was 83% lower in fully treated vs untreated periods (IRR 0.17 [95% CI 0.14, 0.20]), and 78% lower in areas with 80-100% wMel prevalence compared to areas with 0-20%
conclusionsDeployments of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.